LKFT.AS LAKEFRONT BIOTHERAPEUTICS NV
- Market cap
- EUR 1.92B
- P/E
- 3.2x
- P/B
- 0.57x
- ROE
- 1.0%
- Dividend yield
- -
- Fundamental score
- 2.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LKFT.AS undervalued?
Graham numberThe Graham number of LAKEFRONT BIOTHERAPEUTICS NV cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LAKEFRONT BIOTHERAPEUTICS NV fundamental analysis
12 of 22 checks passedROE 0/2
Low return on equity (1.0%), below 10%.
ROA 1/1
Return on assets (1.0%) is above the industry median (-19.8%).
Profit Consistency 1/2
Profitable for 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (333.2%) is above the industry median (3.8%).
Revenue Growth 2/2
Revenue grew 30.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 1/1
PE (3.3x) is below the market median (15.7x).
PE vs Industry 1/1
PE (3.3x) is below the industry median (18.6x).
PBV 1/1
Price to book (0.6x) is below the industry median (3.1x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 1.9, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
LAKEFRONT BIOTHERAPEUTICS NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LAKEFRONT BIOTHERAPEUTICS NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product ca…
Full company profileLAKEFRONT BIOTHERAPEUTICS NV financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LAKEFRONT BIOTHERAPEUTICS NV annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 130M | 127M | 289M | 845M | 478M | 485M | 505M | 240M | 276M | 1.11B | 37.2M |
| Gross Profit | -10.1M | -91.4M | -34.0M | 418M | -45.6M | 483M | 493M | 204M | 241M | 1.03B | 9.29M |
| Operating Income | -11.5M | -89.8M | -44.8M | 370M | -179M | -166M | -268M | -88.3M | -188M | 470M | -217M |
| EBITDA | -8.16M | -110M | -28.9M | 381M | -293M | -101M | 3.87M | 51.0M | 43.3M | 522M | 30.0M |
| Net Income | 54.0M | -116M | -29.3M | 150M | -311M | -125M | -218M | 212M | 74.1M | 321M | 33.2M |
| EPS | 1.18 | -2.34 | -0.56 | 2.60 | -4.78 | -1.91 | -3.32 | 3.21 | 1.12 | 4.87 | 0.51 |
| Balance Sheet | |||||||||||
| Total Assets | 1.08B | 1.29B | 1.44B | 6.07B | 5.72B | 5.19B | 4.73B | 4.36B | 4.14B | 3.41B | 3.35B |
| Total Liabilities | 325M | 274M | 225M | 3.19B | 3.05B | 2.55B | 2.21B | 1.56B | 1.24B | 171M | 87.6M |
| Shareholders' Equity | 759M | 1.01B | 1.21B | 2.88B | 2.67B | 2.64B | 2.53B | 2.80B | 2.90B | 3.24B | 3.26B |
| Cash & Short-term Investments | 973M | 1.15B | 1.29B | 5.78B | 5.16B | 4.70B | 4.09B | 3.68B | 3.12B | 3.00B | 136M |
| Total Debt | 63.0K | 9.00K | - | 25.4M | 29.4M | 26.9M | 21.9M | 9.60M | 11.7M | 6.92M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 239M | -147M | -142M | 3.21B | -427M | -504M | -501M | -406M | -320M | -197M | -225M |
| Capital Expenditure | 4.79M | 7.44M | 13.7M | 45.7M | 91.3M | 57.9M | 36.9M | 19.3M | 82.1M | 13.7M | 304K |
| Free Cash Flow | 235M | -154M | -156M | 3.16B | -519M | -562M | -537M | -425M | -402M | -211M | -226M |
| Ratios | |||||||||||
| ROE | 7.1% | -11.4% | -2.4% | 5.2% | -11.6% | -4.7% | -8.6% | 7.6% | 2.6% | 9.9% | 1.0% |
| ROA | 5.0% | -9.0% | -2.0% | 2.5% | -5.4% | -2.4% | -4.6% | 4.9% | 1.8% | 9.4% | 1.0% |
| Net Profit Margin | 41.7% | -91.0% | -10.1% | 17.7% | -65.1% | -25.9% | -43.1% | 88.3% | 26.9% | 28.9% | 89.3% |
| Debt to Equity | 0.00x | 0.00x | - | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
LAKEFRONT BIOTHERAPEUTICS NV dividends
LAKEFRONT BIOTHERAPEUTICS NV has not paid dividends in the last 9 fiscal years.
Who owns LAKEFRONT BIOTHERAPEUTICS NV
- Insiders 25.36%
- Institutions 43.55%
- Public & others 31.09%
- Shares outstanding 65.9M
- Free float 23.1M
LAKEFRONT BIOTHERAPEUTICS NV company profile
- Company name
- LAKEFRONT BIOTHERAPEUTICS NV
- Ticker
- LKFT.AS
- ISIN
- BE0003818359
- Exchange
- Euronext Amsterdam
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 196
- Fiscal year end
- December
- Address
- SchaliEnhoevedreef 20 T, Mechelen, Belgium, 2800
- Phone
- 32 1 534 29 00
- Website
- lakefrontbio.com
About LAKEFRONT BIOTHERAPEUTICS NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
LAKEFRONT BIOTHERAPEUTICS NV management
10- Mr. Henry O. GosebruchCEO & Executive Director · born 1973
- Mr. Aaron L. CoxChief Financial Officer · born 1984
- Ms. Christina Carlson J.D.Chief Operating Officer
- Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D.Head of Investor Relations
- Mr. Fred W. Blakeslee IIExecutive VP & General Counsel
- Marieke VermeerschHead of Corporate Communication
- Ms. Tania PhilippChief People Officer · born 1972
- Ms. Ellen Van Der AarHead of Development
- Dr. Jeevan ShettyHead of Clinical Development Oncology
- Ruiz AstigarragaHead of Manufacturing Cell Therapy